Leading specialist market access consultancy Partners4Access has announced their gold sponsorship of the biotech industry conference World Orphan Drug Congress (WODC) Europe. The event will take place at Hotel Sofia, Barcelona between November 13-14, 2019.
P4A’s Sophie Schmitz, managing partner; Akshay Kumar, partner; Aparna Krishnan, director and Nicola Allen, associate director will be attending the congress.
On day one, November 13 at 11:30 am, Akshay Kumar and Nicola Allen will be leading the interactive roundtable on ‘Treatments without borders: Solutions for the cross border conundrum’. The discussion will aim to understand the key challenges under the Cross Border Healthcare initiative in the EU and suggest solutions.
On day two, November 14 at 14:10, Sophie Schmitz will be presenting with Darren Walsh, senior director, Orchard Therapeutics on ‘Addressing unique commercial challenges with gene therapy: learnings from Strimvelis’ under the congress’ Cell & Gene Therapy track.
Apart from the speaking engagements, Partners4Access will also be exhibiting their orphan drugs, cell and gene therapy based solutions on stand #10 and Aparna Krishnan will be on site to podcast from the event.
WODC organized by Terrapinn brings together a global gathering of over 600 attendees from 275 companies specializing in orphan drugs, featuring over 200 speakers covering all aspects of orphan drug development, market access, cell and gene therapy, advocacy and rare disease research. For more details, please visit the Terrapinn website here.
Partners4Access are experts in orphan drug, cell and gene therapy access, partnering with the biotechnology industry to support launches worldwide. Our services focus on five key areas: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence.
As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access. Through various media initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in striking an equilibrium in the rare disease world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please visit P4A’s website: www.partners4access.com or email at [email protected].